Aydin Huseynov
Stock Analyst at Ladenburg Thalmann
(0.68)
# 4,048
Out of 5,182 analysts
58
Total ratings
32%
Success rate
-29.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Aydin Huseynov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELTX Elicio Therapeutics | Initiates: Buy | $20 | $11.36 | +76.06% | 1 | Apr 15, 2026 | |
| IKT Inhibikase Therapeutics | Initiates: Buy | $4 | $1.89 | +111.64% | 1 | Mar 4, 2026 | |
| AKTX Akari Therapeutics, | Initiates: Buy | $40 | $5.60 | +614.29% | 1 | Jan 5, 2026 | |
| ARDX Ardelyx | Assumes: Buy | $11 | $5.99 | +83.64% | 1 | Mar 7, 2025 | |
| URGN UroGen Pharma | Assumes: Buy | $31 | $23.77 | +30.42% | 1 | Feb 19, 2025 | |
| MRKR Marker Therapeutics | Maintains: Buy | $11 → $19 | $1.45 | +1,210.34% | 2 | Oct 21, 2024 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $12 → $21 | $15.92 | +31.91% | 3 | Sep 16, 2024 | |
| CMPX Compass Therapeutics | Upgrades: Buy | $5 | $1.79 | +179.33% | 2 | Sep 16, 2024 | |
| ACRV Acrivon Therapeutics | Upgrades: Buy | $16 | $1.88 | +751.06% | 3 | Sep 16, 2024 | |
| CLDI Calidi Biotherapeutics | Initiates: Buy | $120 | $0.24 | +50,426.32% | 1 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $25 | $35.10 | -28.77% | 2 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $57.18 | - | 3 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10,000 | $3.32 | +301,104.82% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $1.44 | +386.11% | 1 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $5.41 | +84.84% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $16.40 | +265.85% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $6 | $1.28 | +368.75% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $4.62 | +116.45% | 3 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $375 → $240 | $1.96 | +12,144.90% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $104 → $182 | $1.72 | +10,481.40% | 2 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Speculative Buy | $4,500 → $2,000 | $2.99 | +66,901.68% | 1 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $9.62 | - | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.37 | - | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $8.75 | +140.00% | 1 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10,500 | $5.46 | +192,207.69% | 1 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $1.89 | +1,857.67% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $300 | $86.74 | +245.88% | 3 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $744.44 | - | 6 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $89 | $95.72 | -7.02% | 2 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | n/a | $128.04 | - | 1 | Sep 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $336 | $1.17 | +28,617.95% | 1 | May 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $3.76 | +378.72% | 1 | Mar 19, 2020 |
Elicio Therapeutics
Apr 15, 2026
Initiates: Buy
Price Target: $20
Current: $11.36
Upside: +76.06%
Inhibikase Therapeutics
Mar 4, 2026
Initiates: Buy
Price Target: $4
Current: $1.89
Upside: +111.64%
Akari Therapeutics,
Jan 5, 2026
Initiates: Buy
Price Target: $40
Current: $5.60
Upside: +614.29%
Ardelyx
Mar 7, 2025
Assumes: Buy
Price Target: $11
Current: $5.99
Upside: +83.64%
UroGen Pharma
Feb 19, 2025
Assumes: Buy
Price Target: $31
Current: $23.77
Upside: +30.42%
Marker Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $11 → $19
Current: $1.45
Upside: +1,210.34%
Corvus Pharmaceuticals
Sep 16, 2024
Maintains: Buy
Price Target: $12 → $21
Current: $15.92
Upside: +31.91%
Compass Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $5
Current: $1.79
Upside: +179.33%
Acrivon Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $16
Current: $1.88
Upside: +751.06%
Calidi Biotherapeutics
Jun 27, 2024
Initiates: Buy
Price Target: $120
Current: $0.24
Upside: +50,426.32%
May 14, 2024
Maintains: Buy
Price Target: $24 → $25
Current: $35.10
Upside: -28.77%
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $57.18
Upside: -
Feb 8, 2024
Initiates: Buy
Price Target: $10,000
Current: $3.32
Upside: +301,104.82%
Dec 27, 2023
Initiates: Buy
Price Target: $7
Current: $1.44
Upside: +386.11%
Oct 10, 2023
Initiates: Buy
Price Target: $10
Current: $5.41
Upside: +84.84%
Sep 22, 2023
Initiates: Buy
Price Target: $60
Current: $16.40
Upside: +265.85%
Aug 14, 2023
Maintains: Buy
Price Target: $10 → $6
Current: $1.28
Upside: +368.75%
Jun 5, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $4.62
Upside: +116.45%
May 16, 2023
Maintains: Buy
Price Target: $375 → $240
Current: $1.96
Upside: +12,144.90%
Apr 28, 2023
Maintains: Buy
Price Target: $104 → $182
Current: $1.72
Upside: +10,481.40%
Apr 4, 2023
Maintains: Speculative Buy
Price Target: $4,500 → $2,000
Current: $2.99
Upside: +66,901.68%
Nov 4, 2022
Downgrades: Neutral
Price Target: n/a
Current: $9.62
Upside: -
Aug 23, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.37
Upside: -
Jul 13, 2022
Initiates: Buy
Price Target: $21
Current: $8.75
Upside: +140.00%
May 6, 2022
Initiates: Buy
Price Target: $10,500
Current: $5.46
Upside: +192,207.69%
May 2, 2022
Initiates: Buy
Price Target: $37
Current: $1.89
Upside: +1,857.67%
Nov 8, 2021
Upgrades: Buy
Price Target: $300
Current: $86.74
Upside: +245.88%
Nov 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $744.44
Upside: -
Jul 20, 2021
Upgrades: Buy
Price Target: $89
Current: $95.72
Upside: -7.02%
Sep 30, 2020
Initiates: Hold
Price Target: n/a
Current: $128.04
Upside: -
May 21, 2020
Initiates: Buy
Price Target: $336
Current: $1.17
Upside: +28,617.95%
Mar 19, 2020
Initiates: Buy
Price Target: $18
Current: $3.76
Upside: +378.72%